Showing 161 - 180 results of 98,127 for search '(( 2 a decrease ) OR ((( 50 ((ns decrease) OR (we decrease)) ) OR ( 5 nn decrease ))))', query time: 1.05s Refine Results
  1. 161
  2. 162
  3. 163

    MMP-2 production is decreased following ALK5 inhibition. by Rebecca A. Scott (488956)

    Published 2020
    “…<p>MMP-2 production was decreased in co-cultures treated with 1 μM A83-01 compared to DMSO-treated controls, as detected via ELISA. …”
  4. 164
  5. 165

    DAF-16/FOXO is Required for Locomotory Healthspan and Lifespan Benefits of Genetic Glycolysis Disruption. by Brian Onken (86790)

    Published 2020
    “…The beneficial effects of glycolytic gene disruptions seen in wild-type animals (refer to <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.g001" target="_blank">Fig 1D</a>) are mostly eliminated in the <i>daf-16</i> mutant background: median survival is not increased in <i>daf-16</i> animals treated with either RNAi, and the survival curve of <i>daf-16</i> mutants raised on <i>pyk-2(RNAi)</i> is not significantly (n.s.) different than controls (Log-rank test). …”
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170

    Disrupting Glycolysis-promoting Genes Extends <i>C</i>. <i>elegans</i> Healthspan, Whereas High Glucose and Gluconeogenic Gene Disruptions Shorten Healthspan. by Brian Onken (86790)

    Published 2020
    “…<i>elegans</i> ORF designations indicated). We note that, in our hands, disruption of C50F4.2 (<i>pfk-1</i>.…”
  11. 171

    A randomized trial of a behavioral intervention to decrease hospital length of stay by decreasing bedrest by Juliana Tolles (8282265)

    Published 2020
    “…</p><p>Trial registration</p><p>ClinicalTrials.gov, <a href="https://clinicaltrials.gov/ct2/show/NCT04006990" target="_blank">HS-16-00804</a>.…”
  12. 172

    mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes. by Wakiko Iwata (8600457)

    Published 2020
    “…<p>(<b>A</b>) Primary cultured podocytes were isolated from <i>Tsc2</i><sup>Δ<i>podocyte</i></sup> and wild-type controls, followed by western blot analyses of TSC2, phospho-4EBP1, LC3B type II, p62, phospho-ULK1, and β-tubulin. …”
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180